secwatch.observer — SEC 8-K summary
======================================

Issuer:     Definium Therapeutics, Inc. (DFTX)
CIK:        0001813814
Form:       8-K
Filed at:   2022-11-10T23:59:59+00:00
Accession:  0000950170-22-024182
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

MindMed Q3 net loss $16.5M, cash $154.5M; Phase 2b GAD trial on track for H2 2023 readout
--------------------------------------------------------------------------------

- Net loss of $16.5M for Q3 2022 vs $17.2M in Q3 2021; nine-month net loss $51.9M vs $76.2M.
- Cash and equivalents $154.5M as of Sept 30, 2022; expected to fund operations into first half of 2025.
- Raised ~$60M in gross proceeds via at-the-market program and public offering during Q3.
- Phase 2b dose-optimization trial of MM-120 (LSD) in GAD initiated; topline data expected H2 2023.
- Advanced IND-enabling studies for MM-402 (R-MDMA) for autism; Phase 1 planned for 2023.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1813814/000095017022024182/0000950170-22-024182-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1813814/000095017022024182/mnmd-20221110.htm
  HTML page:      https://secwatch.observer/filing/0000950170-22-024182

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer